Food For Thought, page-12

Yes, but it certainy wasn't a case of "Teva did an additional 2 years research before commencing the heart trial this in itself reassures us that this is real technology that works", which is what was posted by a fellow member.

And when you say "MSB products were not a casualty in this which would suggest that the company saw strategic value in continuing with further development of those programs", the only product MSB product (singular) that Teva is involved in is Heart, which many accounts suggest Teva was contractually obliged to continue, anyway.

Another Teva-relevant observation worth making is that they have failed over the years to prevent themselves by being diluted when they had ample opportunity to add to their position at price levels well below the prevailing MSB share price when Teva first became involved with MSB. And it would have cost them very little - in the context of the size of the company they are - to maintain their proportional interest in MSB.

In fact, have a look at MSB threads at the time that Teva acquired Cephalon: there was sure-speak that Teva was going to move to take over MSB.

Today, almost 5 years later, Celgene is the prospective would-be acquirer, seemingly.